Open this publication in new window or tab >>Show others...
2022 (English)In: Antibiotics, E-ISSN 2079-6382, Vol. 11, no 11, article id 1646Article in journal (Refereed) Published
Abstract [en]
Double-carbapenem combinations have shown synergistic potential against carbapenemase-producing Enterobacterales, but data remain inconclusive. This study evaluated the activity of double-carbapenem combinations against 51 clinical KPC-2-, OXA-48-, NDM-1, and NDM-5-producing Escherichia coli and Klebsiella pneumoniae and against constructed E. coli strains harboring genes encoding KPC-2, OXA-48, or NDM-1 in an otherwise isogenic background. Two-drug combinations of ertapenem, meropenem, and doripenem were evaluated in 24 h time-lapse microscopy experiments with a subsequent spot assay and in static time-kill experiments. An enhanced effect in time-lapse microscopy experiments at 24 h and synergy in the spot assay was detected with one or more combinations against 4/14 KPC-2-, 17/17 OXA-48-, 2/17 NDM-, and 1/3 NDM-1+OXA-48-producing clinical isolates. Synergy rates were higher against meropenem- and doripenem-susceptible isolates and against OXA-48 producers. NDM production was associated with significantly lower synergy rates in E. coli. In time-kill experiments with constructed KPC-2-, OXA-48- and NDM-1-producing E. coli, 24 h synergy was not observed; however, synergy at earlier time points was found against the KPC-2- and OXA-48-producing constructs. Our findings indicate that the benefit of double-carbapenem combinations against carbapenemase-producing E. coli and K. pneumoniae is limited, especially against isolates that are resistant to the constituent antibiotics and produce NDM.
Place, publisher, year, edition, pages
MDPI, 2022
Keywords
carbapenem resistance, Gram-negative bacteria, combination therapy, synergy
National Category
Infectious Medicine
Identifiers
urn:nbn:se:uu:diva-492674 (URN)10.3390/antibiotics11111646 (DOI)000894343200001 ()36421290 (PubMedID)
Funder
Swedish Research Council, 2019-05911Vinnova, 2021-02699Swedish Research Council, 2020-02320AFA Insurance, 180124
2023-01-102023-01-102024-07-04Bibliographically approved